Asset Details
Do you wish to reserve the book?
Navigating Gestational Trophoblastic Neoplasia: Lessons From 15 Cases at a North Indian Tertiary Care Center
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Navigating Gestational Trophoblastic Neoplasia: Lessons From 15 Cases at a North Indian Tertiary Care Center
Do you wish to request the book?
Navigating Gestational Trophoblastic Neoplasia: Lessons From 15 Cases at a North Indian Tertiary Care Center
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Navigating Gestational Trophoblastic Neoplasia: Lessons From 15 Cases at a North Indian Tertiary Care Center
2024
Overview
Objective
To evaluate the clinical outcomes and treatment strategies in patients with gestational trophoblastic neoplasia (GTN) treated at a tertiary care center in North India, with a focus on response to methotrexate-based chemotherapy and the factors influencing the need for escalation to more intensive regimens.
Methods
A prospective observational study was conducted on 15 patients diagnosed with GTN from June 2023 to June 2024 at a tertiary care center. The mean age of the cohort was 24.6 years. All patients were initially diagnosed following a molar pregnancy, with a mean interval of 4.57 months between the antecedent pregnancy and diagnosis. Treatment regimens primarily included methotrexate and folinic acid (Mtx + FA), with 23.1% of patients requiring escalation to the more aggressive EMA-CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine) regimen due to inadequate response. Lung metastasis was identified as a key factor leading to treatment escalation.
Results
Of the 15 patients, the majority were initially treated with the Mtx + FA regimen. Approximately 23.1% (n=3) of patients required a switch to the EMA-CO regimen due to insufficient response to the initial treatment. Lung metastasis was a major determinant for escalating therapy in patients who were considered low-risk based on WHO and FIGO staging criteria. Despite these challenges, all patients achieved complete remission, either through initial therapy or after escalation to more aggressive regimens.
Conclusion
This study underscores the significance of individualized treatment approaches for patients with GTN, particularly in the presence of metastasis, to ensure optimal outcomes. Timely risk stratification based on WHO scoring and FIGO staging is critical in determining the appropriate chemotherapy regimen.
Publisher
Springer India,Springer Nature B.V
Subject
